Eli Lilly Builds $1.5 Billion Stock of Experimental Weight-Loss Pill Ahead of April FDA Vote
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its oral weight-loss candidate orforglipron, according to a regulatory filing, as the drug awaits an expected U.S. Food and Drug Administration decision in April. The stockpile compares with nearly $550 million reported the previous year. Orforglipron holds a fast-track review vouche…